1. Home
  2. PRTA

as of 02-19-2026 10:06am EST

$9.05
$0.04
-0.44%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

Founded: 2012 Country:
US
Employees: N/A City: DUBLIN 2
Market Cap: 482.3M IPO Year: 2013
Target Price: $18.86 AVG Volume (30 days): 364.7K
Analyst Decision: Buy Number of Analysts: 9
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -4.13 EPS Growth: 17.75
52 Week Low/High: $4.32 - $16.66 Next Earning Date: 01-01-0001
Revenue: $814,000 Revenue Growth: -14.76%
Revenue Growth (this year): -91.65% Revenue Growth (next year): 1183.79%
P/E Ratio: -2.20 Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

AI-Powered PRTA Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 16 hours ago

AI Recommendation

hold
Model Accuracy: 70.70%
70.70%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest Prothena Corporation plc News

PRTA Breaking Stock News: Dive into PRTA Ticker-Specific Updates for Smart Investing

All PRTA News

Share on Social Networks: